Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non-valvular atrial fibrillation
2023-507544-37-00Phase 3Authorised
- Sponsor
- CHU Caen Normandie
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apixaban in Atrial fibrillation (AFib) and end-stage kidney disease (ESKD) (2 arms), sponsored by CHU Caen Normandie. Primary endpoint: Clinically significant major or non-major bleeding. Planned start May 2024; status: authorised.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2023-507544-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507544-37-00.